Clinical trials: PSC
Primary Sclerosing Cholangitis, Liver Diseases
Primary Sclerosing Cholangitis in Children
Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine.
- Conditions
- Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
- Trial name
- NCT04181138
- Where
- 12 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Arbor Research Collaborative for Health
Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder
Vancomycin in Primary Sclerosing Cholangitis in Italy
Primary sclerosing cholangitis (PSC) is chronic fibroinflammatory disease of the liver. There is still no medical therapy proven to halt the progression of PSC or prevent its serious complications.
- Conditions
- Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder, IBD
- Trial name
- VanC-IT (NCT05876182)
- Testing
- Oral Vancomycin
- Where
- Italy
- Volunteers
- 84 people
- Sponsor
- University of Milano Bicocca
Primary Sclerosing Cholangitis
PSC Clinical Epidemiology in China
Primary sclerosing cholangitis (PSC) is a rare disease but is increasingly reported in China (mainly in the Chinese language). However, most of the PSC literatures reported from China are case reports, small case series, and…
- Trial name
- NCT04981756
- Testing
- observation
- Where
- 3 sites in China
- Volunteers
- 800 people
- Sponsor
- Beijing Friendship Hospital
Cholestasis, Primary Sclerosing Cholangitis
Paternally Inherited Phenotypes in Cholestasis
For some years investigators have known that the health of fathers at the time their baby is conceived has an influence on the health of their child in the future.
- Conditions
- Cholestasis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
- Trial name
- PIP-C (NCT03337074)
- Testing
- Questionnaire, semen sample, fasting blood sample, Questionnaire, Questionnaire, fasting blood sample
- Where
- 2 sites in United Kingdom
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
SARS-CoV-2 Infection
Understanding the Long-term Impact of COVID on Children and Families
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals age 0-25 years who will enter the cohort with and without SARS-CoV-2 infection at varying stages before and after infection.
- Trial name
- NCT05172011
- Where
- 65 sites in United States
- Volunteers
- 15,028 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Primary Sclerosing Cholangitis (PSC)
Genomics of Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC) is a progressive liver disorder of unknown cause. Current evidence suggests that genes, the genetic material we inherit from our parents, in combination with environmental factors, likely play…
- Trial name
- NCT01161992
- Testing
- Genetic Analysis
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Mayo Clinic
Autoimmune Hepatitis, Primary Biliary Cholangitis (PBC)
Deciphering the Self-antigen Specific T Cell Signature of Autoimmune Liver Diseases
The study aims to establish the molecular signature of autoimmune self-antigen-specific T cells in AutoImmune Liver Disease (AILD)
- Conditions
- Autoimmune Hepatitis, Primary Biliary Cholangitis (PBC), Autoimmune Liver Disease, Primary Sclerosing Cholangitis (PSC)
- Trial name
- DISTAL (NCT07784881)
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Nantes University Hospital
Primary Sclerosing Cholangitis, Biliary Atresia
Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
The goals of the proposed work are two fold: Firstly, to see if the antibiotic vancomycin may be used for the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC).
- Trial name
- PSC (NCT01322386)
- Testing
- Vancomycin
- Volunteers
- 32 people
- Sponsor
- Stanford University
Primary Sclerosing Cholangitis, Post- Orthotopic Liver Transplantation
Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients
The purpose of the study is to investigate the safety and efficacy of oral vancomycin in patients with recurrent Primary Sclerosing Cholangitis (PSC) after liver transplantation.
- Trial name
- NCT03046901
- Testing
- Vancomycin
- Where
- United States
- Sponsor
- Ochsner Health System
Trauma Patients
Using a Primary Care- Based Stepped-Care Model of Trauma Focused Cognitive Behavioral Therapy (PSC-TF-CBT)to Reduce Trauma Symptoms and Negative Mental Health Sequelae
The purpose of this study is to evaluating the feasibility of delivering a trauma-focused intervention among children with elevated traumatic stress symptoms in primary care
- Trial name
- NCT07797400
- Testing
- PSC-TF-CBT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center, Houston
Primary Sclerosing Cholangitis
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC.
- Trial name
- SHIP (NCT03561584)
- Testing
- Sulfasalazine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Brigham and Women's Hospital
Post-Acute COVID-19, Post-Acute COVID-19 Syndrome
Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Post-COVID-19 Syndrome: A Randomized Controlled Trial
About 10-20% of persons who contract SARS CoV-2 will experience persistent post-acute sequelae of SARSCoV-2 infection (referred here as PASC).
- Conditions
- Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 Infection, Long COVID
- Trial name
- NCT06156202
- Testing
- Comprehensive Rehabilitation, Augmented Usual Care
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Pennsylvania
Primary Sclerosing Cholangitis
Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis
The objective of this study is to evaluate the improvement of bile duct strictures following the administration of HK-660S in patients with Primary Sclerosing Cholangitis(PSC).
- Trial name
- NCT05866809
- Testing
- HK-660S
- Where
- 4 sites in South Korea
- Volunteers
- 23 people
- Sponsor
- CuromeBiosciences
Leukemia
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
Phase I trial to study the effectiveness of PSC-833 plus etoposide and mitoxantrone in treating children who have refractory or relapsed acute leukemia.
- Trial name
- NCT00002912
- Testing
- etoposide, mitoxantrone hydrochloride, valspodar
- Where
- 55 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Autoimmune Liver Disease, Primary Sclerosing Cholangitis
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents.
- Conditions
- Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
- Trial name
- NCT03175471
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Primary Sclerosing Cholangitis
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared with standard of care alone in the treatment of adolescents and adults with primary sclerosing cholangitis (PSC).
- Trial name
- HAAPS (NCT05295680)
- Testing
- Hymecromone
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Aparna Goel
Primary Sclerosing Cholangitis
norUrsodeoxycholic Acid vs Placebo in PSC
Double-blind, randomized, multi-center, placebo-controlled, comparative, phase III trial. The study will be conducted with two treatment groups in the form of a parallel group comparison and will serve to compare oral treatment…
- Trial name
- NCT03872921
- Testing
- norUrsodeoxycholic Acid
- Where
- 2 sites in Austria, Germany
- Volunteers
- 303 people
- Sponsor
- Dr. Falk Pharma GmbH
Breast Cancer, Cancer
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
This is a dosage escalation study to estimate the maximum tolerated dose of drug resistance inhibitor PSC 833 given in combination with paclitaxel.
- Conditions
- Breast Cancer, Cancer, Carcinoma, Renal Cell, Lymphoma
- Trial name
- NCT00001383
- Testing
- PSC 833, paclitaxel
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PSC 833 may increase the effectiveness of chemotherapy by making cancer cells more sensitive to the drugs.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7)
- Trial name
- NCT00006363
- Testing
- cytarabine, daunorubicin hydrochloride, etoposide
- Where
- United States
- Volunteers
- 720 people
- Sponsor
- National Cancer Institute (NCI)
Primary Sclerosing Cholangitis, Elastography
Disease Status in Primary Sclerosing Cholangitis by Elastography
Primary sclerosing cholangitis (PSC) is a chronic liver disease that can lead to liver cirrhosis, liver failure and liver cancer.
- Conditions
- Primary Sclerosing Cholangitis, Elastography, Hepatic Fibrosis, Magnetic Resonance Imaging
- Trial name
- NCT02446665
- Testing
- MR Elastography (MRE) and FibroScan
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- University Health Network, Toronto